Mitoxantrone (INN, BAN, USAN; also known as Mitozantrone in Australia; trade name Novantrone) is an anthracenedione antineoplastic agent.

The global Mitoxantrone market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Mitoxantrone volume and value at global level, regional level and company level. From a global perspective, this report represents overall Mitoxantrone market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Mitoxantrone in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Mitoxantrone manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Pfizer
Mylan
Teva
Fresenius Kabi
West-Ward Pharmaceuticals
Sichuan Sunnyhope Pharmaceutical
Shandong Luoxin Pharmaceutical
Baxter

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
5 mg Lyophilized powder
20 mg/10 mL multidose vial
25 mg/12.5 mL multidose vial
30 mg/15 mL multidose vial

Segment by Application
Certain types of cancer
Multiple sclerosis (MS)